Quantcast

Industry news that matters to you.  Learn more

Asthmapolis Relaunches as Propeller Health to Advance Broader Respiratory Mission

Asthmapolis, the FDA-cleared mobile health solution for chronic respiratory disease, recently announced the company is changing its name to Propeller Health. The Propeller platform is designed to help patients and their physicians better understand and control respiratory disease to reduce preventable emergency room visits, hospitalizations and unnecessary suffering.

Propeller Health will now offer providers and payers expanded mobile apps for asthma, COPD and other respiratory disease, as well as new sensors for additional inhaled medications pending regulatory clearance.

“COPD is the third leading cause of death in the United States and an extremely costly disease, both in its actual medical costs and the impairments that limit patients with this illness. I believe using technology to help improve adherence and give clinicians early indications of increasing symptoms or exacerbations is valuable and will make an important contribution to helping people successfully manage the disease,” said David Mannino, MD, professor and chair, University of Kentucky Department of Preventive Medicine and Environment, and international expert on the epidemiology and impact of COPD.

Early outcomes have been promising. In the last month, more than two-thirds of Propeller users with asthma were well-controlled or transitioned to well-controlled; by comparison, only 30-40 percent of the general population with asthma has their disease under control. In recent programs, up to 80 percent of patients with asthma remain engaged with Propeller three to six months after enrollment. As a result, the Propeller platform has yielded an 80 percent improvement in medication adherence.

“We need to be doing everything we can to help people manage their health conditions and prevent unnecessary trips to the hospital,” said Rich Roth, vice president of strategic innovation at Dignity Health. “Propeller Health is in a position to make big difference for our patients, which is why we’re excited to see the company moving in this direction.”

Propeller is a novel combination of snap-on sensors, mobile apps, analytics and personal services to empower people to achieve better self-management of their respiratory disease, while reducing the burden of chronic disease management. The HIPAA-compliant solution uses remote monitoring to track when and how often patients use their inhaled medications. This real-time information advances understanding of symptoms and triggers and reveals insights about both medication adherence and rescue medication frequency. Analytics coupled with personalized feedback and individual support, including access to health educators and community managers, inform more productive conversations between Propeller users and their care teams, contributing to positive behavior change, improved quality of life and reduced costs to manage chronic disease like asthma and COPD.

“Over the last year, we’ve grown to be the leading mobile health platform for managing asthma. Today we are charting a new course in chronic respiratory disease management, applying our proven technology and accumulated wisdom to reduce healthcare utilization for COPD,” said David Van Sickle, CEO of Propeller Health. “The Propeller brand broadens our mobile health footprint to include all disease treated with inhaled medications. It more accurately describes how we use technology to achieve momentum in self-management, but with minimal disruption to our users’ daily lives, which in turn helps improve outcomes that reduce cost.”

“Asthmapolis, now Propeller Health, is one of the leaders in mobile health sensors and apps. It is great to see their expansion from asthma to COPD,” said Eric Topol MD, CAO of Scripps Health and author of The Creative Destruction of Medicine (Topol has no relationship with the company). “Further, someday in the future there is now hope that such a platform will be able to markedly reduce asthma attacks and exacerbations of COPD.”

Propeller for COPD is available now, and the company is filing applications for international regulatory clearance for additional sensors later this year.

Source: Propeller Health

Almac Offering TruSight Tumor Profiling Next-Generation Sequencing Service

Almac recently announced they are now offering a Tumor Profiling service running Illumina’s next-generation sequencing (NGS) TruSight Tumor™ panel as part of their biomarker discovery, development and delivery solutions.

Almac, a personalised medicine company with CAP accredited and CLIA certified laboratories, extends their portfolio of services by offering TruSight Tumor™ to complement its current range of RNA, DNA and protein based technologies for biomarker analysis.

Almac is currently running many bespoke diagnostic assays for pharma customers for early phase clinical trial enrichment. The TruSight Tumor™ panel enables additional profiling of these patient samples to provide Almac’s pharma partners with further important information on emerging biomarkers that may also impact drug response.
The TruSight Tumor™ panel was developed by Illumina for their MiSeq® system, allowing targeted DNA sequencing and reporting on the mutation status of 26 genes which are most commonly mutated in solid tumors including lung, colon, ovarian, melanoma and gastric cancers.

One of Almac’s key strengths is many years of experience in working with formalin fixed paraffin embedded (FFPE) tissue. The TruSight Tumor™ panel is specifically designed for use with FFPE samples, and enables the highest levels of sensitivity for mutation detection with limited DNA input requirements.

“Almac is committed to the development of personalised medicine through the delivery of a wide range of innovative solutions. We are pleased to announce the expansion of our NGS service to include TruSight Tumor™” said Professor Paul Harkin, President and Managing Director of Almac’s Diagnostic business unit.

Source: Almac

Caris Life Sciences Expands Global Reach of its Tumour Profiling Service to Middle East and Africa

Caris Life Sciences™, a leading biosciences company focused on fulfilling the promise of personalized medicine in oncology, recently signed a distribution agreement with IPS Genomix to facilitate patient access to its tumour profiling service, Molecular Intelligence™, in select Middle Eastern and African markets. Given this region’s continued investment in healthcare, Caris is uniquely positioned to provide a growing community of oncologists the most relevant and actionable biomarker information to help individualise cancer care.

“The Middle Eastern and African markets represent key areas of unmet medical need and commercial opportunity for Caris Life Sciences, and demonstrate a significant leap forward for our international global expansion plans,” said Ian Walker, Vice President – International at Caris Life Sciences. “Partnering with IPS Genomix offers us a large, diverse and experienced team to help realize our goal to bring Caris Molecular Intelligence to patients and physicians across the globe.”

Caris Molecular Intelligence™ uses multiple evidence-guided profiling technologies — IHC, FISH/CISH, PCR and Next-Generation Sequencing – to provide oncologists with the most relevant, clinically actionable treatment information to help them personalise care for their patient. By identifying the biomarkers unique to a patient’s tumor, Caris can help the physician develop a treatment plan ranging from commercially available agents to active, openly enrolling clinical trials in the patient’s geography. Caris’ multi-technology approach assesses the molecular biology of a tumor in order to better understand the gene and protein alterations that may be driving its growth. Testing of multiple clinically relevant analytes in a tumor is typically most applicable for patients with aggressive, rare or refractory cancers where standard-of-care guidelines have been exhausted or are unclear, or where additional clinical trial options are desired.

“With more than 25 years of experience in the Middle Eastern and African healthcare markets and the dedicated diagnostics sales, marketing, customer service and medical expert teams needed to successfully interface with the local oncology community, IPS Genomix is an ideal partner to Caris as it strives to broaden the reach of its tumour profiling service,” said Ahmed Yacout, Chairman and CEO of IPS Group. “Our vision is to have a life-changing impact on our community by democratizing access to global health solutions.”

Source: Caris Life Sciences

Genalyte and Barbara Davis Diabetes Center Collaborate to Advance Multiplexed Antigen Panel for Early Diagnosis of Type 1 Diabetes

Genalyte, Inc. recently announced the launch of its Type 1 Diabetes (T1D) antigen panel that runs on the Maverick Detection System. The Genalyte T1D antigen panel is the first multiplexed assay that measures seven autoantibodies associated with the destruction of pancreatic islet cells seen in type 1 diabetes. In a related development, Genalyte reported that it is collaborating with the Barbara Davis Center for Childhood Diabetes (BDC) at the University of Colorado School of Medicine to further develop and test multiplexed antigen panels for the early detection of T1D.

The Genalyte T1D antigen panel was developed as part of the first phase of a Small Business Innovation Research (SBIR) grant awarded to Genalyte to develop multiplexed assays for the early detection and monitoring of type 1 diabetes. The $500,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases also provides support for expansion of the approach to allow autoantibody response profiling by multiple criteria, which is expected to enhance the ability of researchers and clinicians to detect and monitor the development of the disease.

Martin Gleeson, PhD, Chief Scientific Officer of Genalyte, noted, “The pioneering work of Drs. George Eisenbarth and Liping Yu at BDC established assays for the measurement of islet autoantibodies. These rogue elements of the immune system eventually destroy the pancreatic islet cells that produce insulin. The unique capabilities of our Maverick detection platform have the potential to provide researchers and clinicians with tools to detect and track this process from an early stage, when interventions to interrupt the disease process may be feasible.”

An estimated three million individuals in the U.S. have T1D, an autoimmune disorder that leads to life-long dependence on insulin injections. New disease-modifying therapies may have the potential to reduce or stop the destruction of islet cells in patients at risk of developing T1D. The availability of tools to identify these patients early in the disease process would facilitate the development and use of these preventative therapies.

“We are pleased to offer our innovative T1D antigen panel to diabetes researchers worldwide at the same time that we are working with Dr. Liping Yu and his lab at the Barbara Davis Diabetes Center to expand the utility of the approach,” added Dr. Gleeson. “BDC is a long-time leader in the quest to develop curative therapies for type 1 diabetes, and we are delighted to collaborate with them to develop the tools that may help make this dream a reality.”

The Genalyte T1D antigen panel requires only a 2 to 5 μL serum or plasma sample and provides results in less than 15 minutes, without the use of dyes, fluorescent probes or radioactive labels. The T1D panel measures autoantibodies to insulin, proinsulin, GAD 65, GAD 67, IA-2 (PTPRN, ICA512), phogrin (PTPRN2, IA-2ß) and ZnT8 (SLC30A8). For more information, visit http://genalyte.com/maverick-type-1-diabetes-t1d-assay-kit/.

Other commercially available tests for the Maverick Detection System include MT-ADA, ENA 4, ENA 6 and ANA 14 assay kits. Additionally, Genalyte offers researchers a Custom Spotting Service that loads proteins supplied by customers, such as antibodies, peptides, biomarkers, cytokines and antigens, on to standard-format Genalyte chips that are ready to be run on the Maverick System.

Maverick assays are currently available for research use only.

Source: Genalyte

MicroConstants Expands Biomarker Testing and Analysis Services for Preclinical and Clinical Diagnostic Research

MicroConstants, a Contract Research Organization (CRO) specializing in regulated bioanalysis and DMPK, recently announced the appointment of Doinita Serban, Ph.D. as director of biomarker research to oversee the expansion of biomarker testing and analysis services for preclinical and clinical diagnostic research. Doinita’s extensive experience with biomarker assay development, validation, and profiling of disease panels, coupled with the implementation of the Luminex platform, will enable MicroConstants to broaden their biomarker analysis capabilities to include additional assay formats, such as multiplex immunoassays, gene expression and profiling assays.